| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Silke Appel | Q45423552 |
| P2093 | author name string | Stefan Balabanov | |
| Lothar Kanz | |||
| Tim H Brümmendorf | |||
| Peter Brossart | |||
| P2860 | cites work | Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia | Q24599829 |
| NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses | Q27861101 | ||
| NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase | Q28144326 | ||
| Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha | Q28251443 | ||
| Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells | Q28277030 | ||
| Expression of relB is required for the development of thymic medulla and dendritic cells | Q28594949 | ||
| Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia | Q29547900 | ||
| Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors | Q29618610 | ||
| Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome | Q33336718 | ||
| A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias | Q33343973 | ||
| Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia | Q34183674 | ||
| Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family | Q34317095 | ||
| Dendritic cells in cancer vaccines | Q34430740 | ||
| Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies | Q34564857 | ||
| Imatinib alone and in combination for chronic myeloid leukemia | Q35058697 | ||
| Identification of dendritic cell colony-forming units among normal human CD34+ bone marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and t | Q36365774 | ||
| Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified | Q36367631 | ||
| Asymmetric cell divisions sustain long-term hematopoiesis from single-sorted human fetal liver cells | Q36401797 | ||
| CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells | Q37698653 | ||
| ARG tyrosine kinase activity is inhibited by STI571. | Q40814460 | ||
| Origin, maturation and antigen presenting function of dendritic cells. | Q40906220 | ||
| Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. | Q41056381 | ||
| Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL | Q42139163 | ||
| Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation | Q42834585 | ||
| Dendritic cell survival and maturation are regulated by different signaling pathways. | Q42971737 | ||
| Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro | Q43833442 | ||
| Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia | Q43899710 | ||
| Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study | Q43904522 | ||
| Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. | Q43977683 | ||
| Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation | Q43977712 | ||
| Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta | Q44104227 | ||
| Effects of imatinib on bone marrow engraftment in syngeneic mice. | Q44117835 | ||
| Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment | Q44308354 | ||
| Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias | Q44319713 | ||
| Polycythemia vera responds to imatinib mesylate | Q44364237 | ||
| Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. | Q44443441 | ||
| Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro | Q44451881 | ||
| Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera | Q44452184 | ||
| The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia | Q44475743 | ||
| Inhibitory effect of imatinib on normal progenitor cells in vitro | Q44582245 | ||
| Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors | Q44582801 | ||
| Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. | Q44592666 | ||
| Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo | Q44771609 | ||
| Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo | Q44853266 | ||
| Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias | Q45034611 | ||
| Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance | Q45083314 | ||
| Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K/Akt pathway and of IkappaB kinase activity | Q47685303 | ||
| GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells | Q59067424 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | imatinib | Q177094 |
| P304 | page(s) | 168-177 | |
| P577 | publication date | 2005-06-01 | |
| P1433 | published in | Annals of the New York Academy of Sciences | Q2431664 |
| P1476 | title | Effect of tyrosine kinase inhibition using imatinib on normal lymphohematopoietic cells | |
| P478 | volume | 1044 |
| Q58023940 | Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability |
| Q46910193 | Cytogenetic remissions induced by interferon alpha and imatinib mesylate are immunologically distinct in chronic myeloid leukemia. |
| Q46755224 | Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors |
| Q46900475 | Hematological side effects of tyrosine kinase inhibition using imatinib |
| Q46859831 | Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides |
| Q39511922 | Inhibitory effect of soluble platelet-derived growth factor receptor β on intraosseous growth of breast cancer cells in nude mice |
Search more.